Hospital Acquired Disease Testing Market Continues to Expand with Luminex Corporation receiving the U.S. FDA Approval for its ARIES MRSA Assay for Detection of MRSA

 


Testing for hospital-acquired diseases can be done in a number of different ways. If the disease is new, hospital-acquired infections may be contracted from an infected person on the job. In such cases, hospital-acquired infections are commonly referred to as occupational-related diseases. As with other types of diseases, these infections can be caught through simple hand-to-mouth contact. The various methods of testing for this disease include clinical diagnostics and blood tests. If the clinical symptoms do not occur or present themselves slowly, laboratory testing is advisable. However, because symptoms can be similar to those of other diseases that affect the immune system, it is important to obtain a correct diagnosis.

Increasing incidence of hospital-acquired infections is expected to drive growth of the global hospital acquired disease testing market. According to the World Health Organization (WHO), of every 100 hospitalized patients 10 from emerging and 7 from developed countries will acquire at least one healthcare-related infection. According to the European Centre for Disease Prevention and Control, around 7.1% of Europeans get affected by hospital-acquired infections. Adequate sterilization and robust testing equipment can minimize the possibility of such infections and reduce healthcare expenditure. Hence, such factors are expected to drive growth of the global hospital disease testing market. Furthermore, increasing launching of novel and efficient testing tools is expected to propel the global hospital acquired disease testing market growth in the near future. For instance, in December 2019, Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval for its Cobas ivoDx MRSA, a diagnostic test designed to detect the Methicillin-resistant Staphylococcus aureus (MRSA) bacteria.

Decreasing the prevalence of nosocomial infections due to the presence of advanced testing kits is expected to hamper the global hospital-acquired disease testing market growth in the near future. Among regions, North America is expected to witness significant growth in the global hospital-acquired disease testing market. This is owing to the presence of robust healthcare infrastructure and key market players such as Nordion Inc. and Luminex Corporation in the region. Furthermore, Europe is expected to register a lucrative growth rate, owing to increasing investment in healthcare infrastructure in the region.

Key companies involved in the global hospital acquired disease testing market are Luminex Corporation, Biomérieux, Diatherix Laboratories, F.Hoffmann-La Roche Ltd., Life Technologies, Qiagen GmbH, Cantel Medical Corporation, Nordion Inc., Meridian Biosciences Inc., and Cepheid.

For instance, in October 2019, Luminex Corporation received the U.S. FDA 510(k) clearance ARIES MRSA Assay for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA.


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers aroun...
Read more

High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

Image
  Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers. Market Dynamics R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market . For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 ...
Read more

Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

Image
  Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened. Market Dynamics: Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market . For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 ne...
Read more